vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $21.0K, roughly 28507.8× AIM ImmunoTech Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -19881.0%, a 19921.8% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -53.3%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -27.5%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
AIM vs EXEL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2026
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $598.7M |
| Net Profit | $-4.2M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | -14057.1% | 39.3% |
| Net Margin | -19881.0% | 40.8% |
| Revenue YoY | -53.3% | 5.6% |
| Net Profit YoY | 30.0% | 74.8% |
| EPS (diluted) | $-6.46 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $21.0K | $597.8M | ||
| Q3 25 | $26.0K | $568.3M | ||
| Q2 25 | $25.0K | $555.4M | ||
| Q1 25 | $16.0K | $566.8M | ||
| Q4 24 | $45.0K | — | ||
| Q3 24 | $35.0K | $539.5M | ||
| Q2 24 | $50.0K | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-4.2M | $193.6M | ||
| Q3 25 | $-3.3M | $184.8M | ||
| Q2 25 | $-2.8M | $159.6M | ||
| Q1 25 | $-3.7M | $139.9M | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-3.7M | $118.0M | ||
| Q2 24 | $-1.8M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | -14057.1% | 39.6% | ||
| Q3 25 | -9411.5% | 37.6% | ||
| Q2 25 | -10584.0% | 33.6% | ||
| Q1 25 | -22618.8% | 28.8% | ||
| Q4 24 | -13011.1% | — | ||
| Q3 24 | -12825.7% | 25.2% | ||
| Q2 24 | -7388.0% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | -19881.0% | 32.4% | ||
| Q3 25 | -12630.8% | 32.5% | ||
| Q2 25 | -11176.0% | 28.7% | ||
| Q1 25 | -23156.3% | 24.7% | ||
| Q4 24 | -13260.0% | — | ||
| Q3 24 | -10571.4% | 21.9% | ||
| Q2 24 | -3672.0% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-6.46 | $0.69 | ||
| Q3 25 | $1.57 | $0.65 | ||
| Q2 25 | $-3.68 | $0.55 | ||
| Q1 25 | $-0.05 | $0.47 | ||
| Q4 24 | $-21.80 | — | ||
| Q3 24 | $-6.00 | $0.40 | ||
| Q2 24 | $-3.00 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $1.1B |
| Total DebtLower is stronger | $4.5M | — |
| Stockholders' EquityBook value | $-9.8M | $2.2B |
| Total Assets | $5.8M | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $3.0M | $988.5M | ||
| Q3 25 | $2.4M | $791.1M | ||
| Q2 25 | $835.0K | $1.0B | ||
| Q1 25 | $2.2M | $1.1B | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $7.2M | $1.2B | ||
| Q2 24 | $10.1M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $-9.8M | $2.2B | ||
| Q3 25 | $-6.1M | $2.0B | ||
| Q2 25 | $-6.5M | $2.1B | ||
| Q1 25 | $-3.9M | $2.2B | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $2.9M | $2.3B | ||
| Q2 24 | $6.1M | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $5.8M | $2.8B | ||
| Q3 25 | $5.5M | $2.7B | ||
| Q2 25 | $4.1M | $2.8B | ||
| Q1 25 | $6.2M | $2.9B | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $13.6M | $3.0B | ||
| Q2 24 | $15.7M | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $333.5M |
| Free Cash FlowOCF − Capex | — | $332.4M |
| FCF MarginFCF / Revenue | — | 55.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $-2.0M | $290.3M | ||
| Q3 25 | $-5.1M | $49.0M | ||
| Q2 25 | $-1.5M | $211.4M | ||
| Q1 25 | $-2.4M | $240.3M | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $-3.1M | $271.3M | ||
| Q2 24 | $-3.0M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
